Bitcoin faces strong resistance near $88,000 due to selling pressure from investors who bought in the last two years and recent outflows from US spot Bitcoin ETFs. Despite this, Bitcoin holds key support around $80,000, helped by reduced losses among long-term holders and significant buy orders. The market remains sensitive to macroeconomic factors, especially higher US inflation and potential Federal Reserve rate hikes. A sustained move above $88,000 would indicate buyers absorbing selling pressure, while a drop below $80,000 could lead to further declines toward $78,000.
Bitcoin's resistance near $88,000 is noted alongside Pluang's market breadth where 6 out of 50 major cryptocurrencies rose and 43 fell today. For readers following cryptocurrency markets, here is Pluang's snapshot as of Oct 15, 2026 01:31 WIB: EOS gained 8.13% to Rp12.649 with a typical hold time of 87 days, BAT declined 7.52% with 78% buy order activity and a typical hold time of 93 days, and SAND dropped 7.41% with balanced buy/sell orders and a typical hold time of 123 days.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
